Sponsor Pipeline

ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
3
Active Trials
2
Recruiting
2
Disease Areas
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-07-23 NCT07593027
A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial…		 Primary endpoint(s) modified
2026-07-23 NCT07593027
A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial…		 Trial sites reduced: 32 -> 29 locations
Active Trials by Phase
Phase 1/2
3
Active Trials
NCT IDTitleConditionStatus
Phase 1/2
NCT06535412 A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus Systemic Lupus Erythematosus Recruiting
NCT07593027 A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial… Pulmonary Arterial Hypertension PAH Recruiting
NCT06557174 A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients Neuromyelitis Optica Spectrum Disorder (NMOSD) Not Yet Recruiting
Disease Areas
Lupus (SLE) (1) Hypertension (1)
Get alerts when ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free